Proteasome inhibitors in lung cancer
- 20 January 2006
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 58 (3) , 177-189
- https://doi.org/10.1016/j.critrevonc.2005.12.001
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitorsOncogene, 2005
- The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implicationsEuropean Journal Of Cancer, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Prognostic significance of p27KIP1 expression in resected non–small cell lung cancers: Analysis in combination with expressions of p16INK4A, pRB, and p53Journal of Surgical Oncology, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002